Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 26.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 62,555 shares of the company's stock after buying an additional 12,947 shares during the quarter. Hennion & Walsh Asset Management Inc. owned approximately 0.13% of Immunocore worth $1,856,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also bought and sold shares of IMCR. GF Fund Management CO. LTD. purchased a new position in Immunocore in the fourth quarter worth $25,000. NEOS Investment Management LLC grew its holdings in Immunocore by 10.9% in the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock worth $330,000 after purchasing an additional 1,102 shares during the last quarter. Tema Etfs LLC purchased a new position in Immunocore in the fourth quarter worth $330,000. Virtus ETF Advisers LLC grew its holdings in Immunocore by 39.0% in the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company's stock worth $340,000 after purchasing an additional 3,238 shares during the last quarter. Finally, XTX Topco Ltd grew its holdings in Immunocore by 22.2% in the fourth quarter. XTX Topco Ltd now owns 18,896 shares of the company's stock worth $557,000 after purchasing an additional 3,437 shares during the last quarter. 84.50% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Immunocore
In other news, Director Bros. Advisors Lp Baker acquired 807,338 shares of the business's stock in a transaction on Monday, March 17th. The stock was bought at an average price of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the acquisition, the director now owns 2,144,060 shares of the company's stock, valued at approximately $63,721,463.20. This represents a 60.40% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 10.40% of the stock is currently owned by insiders.
Immunocore Stock Performance
NASDAQ IMCR traded down $0.77 on Friday, reaching $37.25. 549,586 shares of the company's stock traded hands, compared to its average volume of 372,294. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of -39.21 and a beta of 0.83. The stock has a 50 day moving average price of $30.23 and a 200-day moving average price of $30.20. Immunocore Holdings plc has a fifty-two week low of $23.15 and a fifty-two week high of $43.12. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78.
Immunocore (NASDAQ:IMCR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.45. The company had revenue of $125.13 million during the quarter, compared to the consensus estimate of $108.82 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The firm's quarterly revenue was up 33.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.49) earnings per share. Equities research analysts predict that Immunocore Holdings plc will post -0.94 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities analysts have issued reports on IMCR shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $71.00 price target on shares of Immunocore in a report on Thursday, April 10th. Wall Street Zen lowered shares of Immunocore from a "buy" rating to a "hold" rating in a report on Friday. Oppenheimer lifted their price target on shares of Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Immunocore in a research note on Tuesday, May 27th. They set a "buy" rating and a $65.00 price objective for the company. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Immunocore from $54.00 to $50.00 and set an "overweight" rating for the company in a research note on Monday, April 14th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $58.89.
Get Our Latest Report on Immunocore
About Immunocore
(
Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Further Reading
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
